Chimeric Antigen Receptor T Cell Therapies For Cancer E Book

Author : Daniel W. Lee,Nirali N. Shah
Publisher : Elsevier Health Sciences
Page : 246 pages
File Size : 54,8 Mb
Release : 2019-11-30
Category : Medical
ISBN : 9780323755979

Get Book

Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book by Daniel W. Lee,Nirali N. Shah Pdf

From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy.

Author : Daniel W. Lee,Nirali N. Shah
Publisher : Elsevier Health Sciences
Page : 0 pages
File Size : 54,6 Mb
Release : 2019-12-02
Category : Medical
ISBN : 0323661815

Get Book

Chimeric Antigen Receptor T-Cell Therapies for Cancer by Daniel W. Lee,Nirali N. Shah Pdf

From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy.

Author : Kamilla Swiech,Kelen Cristina Ribeiro Malmegrim,Virginia Picanco-Castro
Publisher : Unknown
Page : 128 pages
File Size : 52,6 Mb
Release : 2020
Category : Antigens
ISBN : 1071601466

Get Book

Chimeric Antigen Receptor T Cells by Kamilla Swiech,Kelen Cristina Ribeiro Malmegrim,Virginia Picanco-Castro Pdf

Author : Nicolaus Kröger,John Gribben,Christian Chabannon,Ibrahim Yakoub-Agha,Hermann Einsele
Publisher : Springer Nature
Page : 221 pages
File Size : 53,8 Mb
Release : 2022-02-07
Category : Medical
ISBN : 9783030943530

Get Book

The EBMT/EHA CAR-T Cell Handbook by Nicolaus Kröger,John Gribben,Christian Chabannon,Ibrahim Yakoub-Agha,Hermann Einsele Pdf

This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills.

Author : Mumtaz Y. Balkhi
Publisher : Academic Press
Page : 92 pages
File Size : 55,5 Mb
Release : 2019-07-31
Category : Medical
ISBN : 9780128197479

Get Book

Basics of Chimeric Antigen Receptor (CAR) Immunotherapy by Mumtaz Y. Balkhi Pdf

Basics of Chimeric Antigen Receptor (CAR) Immunotherapy presents the latest on how T cell adoptive immunotherapy has progressed in its ultimate goal of curing metastatic malignant cancers. Recent clinical data obtained with checkpoint receptor blockade inhibitors and chimeric antigen receptor (CAR) therapy has been especially promising, thus generating renewed hope that we may be on the verge of finally curing cancer. Over the years, huge progress has been made in controlling several stage IV metastasized cancers through the clinical application of checkpoint receptor inhibitory drugs and CAR-Therapy that has seen unprecedented interest in the immunotherapy field. Presents the first book to provide a basic understanding of chimeric antigen receptor (CARs) design, production and clinical application protocols Provides unique authority as the editor has worked directly with CARs Discusses the challenges encountered in actual clinical trials and how these challenges can be overcome Includes a full chapter on various challenges researchers should expect to encounter in the CAR-therapy field

Author : Armin Ghobadi,John F. DiPersio
Publisher : Springer Nature
Page : 371 pages
File Size : 44,8 Mb
Release : 2022-01-01
Category : Medical
ISBN : 9783030878498

Get Book

Gene and Cellular Immunotherapy for Cancer by Armin Ghobadi,John F. DiPersio Pdf

Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL). These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including CAR-T, TCR-T, TIL, Viral CTLs, NK cells in addition to T/NK cell engagers, focusing on their historical perspectives, biology, development and manufacturing, toxicities and more. Edited by two leading experts on gene and cellular immunotherapy, the book will feature chapters written by a diverse collection of recognized and up-and-coming experts and researchers in the field, providing oncologists, immunologists, researchers and clinical and basic science trainees with a bench to bedside view of the latest developments in the field.

Author : Robert E Hawkins
Publisher : World Scientific
Page : 212 pages
File Size : 42,5 Mb
Release : 2014-05-05
Category : Medical
ISBN : 9789814618533

Get Book

Cellular Therapy Of Cancer: Development Of Gene Therapy Based Approaches by Robert E Hawkins Pdf

Cancer research has progressed enormously in recent years. This review volume will address recent findings in the area of T-cell therapy for cancer, including use of tumour infiltrating lymphocytes (TILs) as a therapy for melanoma, choice of target antigens, advances in engineered receptors, methods of gene transfer to T cells, review of cell processing methods and clinical trial design. Written by leadings scientists in the field, this up-to-date review on cancer research will be an important reference source to the researchers and healthcare professionals in the field.

Author : Katy Rezvani,Rohtesh S. Mehta
Publisher : Frontiers Media SA
Page : 182 pages
File Size : 54,7 Mb
Release : 2020-01-16
Category : Electronic
ISBN : 9782889633784

Get Book

Cellular Therapies in Cancer by Katy Rezvani,Rohtesh S. Mehta Pdf

Author : Richard J. Buka,Ankit J. Kansagra
Publisher : Karger Medical and Scientific Publishers
Page : 71 pages
File Size : 48,9 Mb
Release : 2021-02-28
Category : Medical
ISBN : 9783318067415

Get Book

Fast Facts: CAR T-Cell Therapy by Richard J. Buka,Ankit J. Kansagra Pdf

Chimeric antigen receptor (CAR) T cells are genetically engineered immune cells that can seek out and destroy cancer cells. The results from their use in cancer immunotherapy have been very promising, but treatment is often associated with frequent, serious short-term toxicities. 'Fast Facts: CAR-T Therapy' explains what CAR T cells are and how they were developed, discusses the results of clinical trials and the management of toxicities, and outlines future improvements and applications. It is ideal reading for any healthcare professional wanting to know more about this exciting therapeutic field. Table of Contents: • CAR T cells • Clinical application • Practical aspects • Future directions

Author : Prashant Trikha,Monica Thakar,Conrad Russell Cruz
Publisher : Frontiers Media SA
Page : 192 pages
File Size : 46,7 Mb
Release : 2020-03-24
Category : Electronic
ISBN : 9782889635641

Get Book

Current Perspectives, Challenges and Advances in Cell Based Therapies by Prashant Trikha,Monica Thakar,Conrad Russell Cruz Pdf

Author : Caron A Jacobson,Parth S. Shah
Publisher : Elsevier Health Sciences
Page : 193 pages
File Size : 41,7 Mb
Release : 2023-10-12
Category : Medical
ISBN : 9780443183010

Get Book

CAR T-Cell, An Issue of Hematology/Oncology Clinics of North America, E-Book by Caron A Jacobson,Parth S. Shah Pdf

In this issue of Hematology/Oncology Clinics, guest editors Drs. Caron A. Jacobson and Parth S. Shah bring their considerable expertise to the topic of CAR T-Cell Therapy. Top experts in the field discuss the multiple ways CAR T-cell therapy can be used to help fight a variety of cancers, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL). Contains 12 practice-oriented topics including CAR T-cells in aggressive B-cell lymphomas; CAR T-cells in multiple myeloma; CAR T-cells in AML; mechanisms of resistance of CAR T-cell therapy; the role of CAR T-cell therapy in the era of bispecific antibodies; and more. Provides in-depth clinical reviews on CAR T-cell therapy, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

Author : Anand Rotte,Matthew John Frigault, Binod Dhakal ,Christopher Heery
Publisher : Frontiers Media SA
Page : 129 pages
File Size : 53,8 Mb
Release : 2024-04-22
Category : Medical
ISBN : 9782832548325

Get Book

Emerging Learnings in Cell Therapy: Novel Binding Domains, Universal CAR-T Cells, and More by Anand Rotte,Matthew John Frigault, Binod Dhakal ,Christopher Heery Pdf

The Past decade has seen significant advances in cancer immunotherapy with the development of multiple strategies including monoclonal antibodies targeting checkpoint blockers, oncolytic viruses, fusion proteins and cell therapies such as tumor-specific chimeric antigen receptor (CAR-) T cell therapy, NK cell therapy and γδ-T-cell therapy. Multiple cell therapies including sipuleucel-T (Provange), axicabtagene ciloleucel (Yescarta), brexucabtagene autoleucel (Tecartus), tisagenlecleucel (Kymriah), lisocabtagene maraleucel (Breyanzi), idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti) have been approved by the US FDA for different hematological cancers and hormone-refractory prostate cancer (Provange). Impressive results were noted with CAR-T cell therapy with objective response rates (ORR) as high as 100% in certain hematological cancers and with responses durable over 10 years in some patients.

Author : Asha B. Pillai,Rizwan Romee
Publisher : Frontiers Media SA
Page : 132 pages
File Size : 55,9 Mb
Release : 2023-09-13
Category : Science
ISBN : 9782832534908

Get Book

Innate Immune Cell Therapy of Cancer by Asha B. Pillai,Rizwan Romee Pdf

Adoptive cellular immunotherapy of cancer, particularly chimeric antigen receptor-transduced T cell (CAR-T) therapies, have enjoyed an explosion of clinical trials and translational and basic research in the past decade. The concept and design of the CAR, though originally intended to optimize targeting of innate natural killer cells (NK cells) to tumor-specific antigens, was laterally applied in the past decade to conventional autologous and later third-party allogeneic T cells with first-in-kind successes in leukemia immunotherapy in both adults and children. This approach also spawned the development of an entire industry focused on cancer immunotherapy, laying the foundation for the current paradigm shifts away from toxic chemo/radiotherapy to immune targeting. Aside from cytokine-release toxicities, specific obstacles plaguing existing CAR-T cell therapies include suboptimal killing by fatigued or senescent autologous patient-derived T cells derived, acquisition of tumor resistance to T-cell based immune therapies, and graft-versus-host disease (GVHD) associated with allogeneic conventional T cell therapies.

Author : Avery Dexter Posey, Jr.,John - Maher,Marcela V. Maus
Publisher : Frontiers Media SA
Page : 164 pages
File Size : 43,5 Mb
Release : 2020-04-24
Category : Electronic
ISBN : 9782889636877

Get Book

CAR-T Cell Therapies for Non-Hematopoietic Malignancies: Taking Off The Training Wheels by Avery Dexter Posey, Jr.,John - Maher,Marcela V. Maus Pdf

Chimeric antigen receptor (CAR) T cell therapies for leukemia (e.g. tisagenlecleucel) and lymphoma (e.g. axicabtagene ciloleucel) have recently received regulatory approval in the United States. Phase I/II trials have demonstrated complete remission of refractory or relapsed tumors in 50% - 94% patients. However, the clinical successes of engineered T cells for the treatment of solid malignancies have thus far been few and far between. Furthermore, several instances of severe and lethal toxicities have arisen due to on-target, off-tumor recognition of antigen by T cell products. Recent advances in phase I trials for solid tumors, as well as in pre-clinical models, have revealed several variables that will be important to consider for the successful use of CAR-T cells in treating solid tumors. These variables include (i) regional versus systemic delivery; (ii) scFv versus ligand interactions; (iii) antigen loss versus escape; (iv) epitope spreading and (v) checkpoint expression on immune cells or tumor cells. Also, there remains outstanding mechanistic questions related to why differences exist in the persistence and tonic signaling of second-generation CD28 versus 4-1BB co-stimulated CAR-T cells. In addition, we are now learning the roles of lympho-depleting regimens (and associated toxicities) in modifying the persistence of engineered T cell therapies. A more comprehensive view of CAR-T cell strategies and important advances, both of pre-clinical and clinical evaluations, in solid tumors is necessary to drive these therapies forward.

Author : Mansoor M. Amiji,Lara Scheherazade Milane
Publisher : Academic Press
Page : 550 pages
File Size : 48,6 Mb
Release : 2021-08-18
Category : Business & Economics
ISBN : 9780128236376

Get Book

Cancer Immunology and Immunotherapy by Mansoor M. Amiji,Lara Scheherazade Milane Pdf

Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches. Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. Comprehensive treaty covering all aspects of immuno-oncology (IO) Novel strategies for delivery of IO therapeutics and vaccines Forecasting on the future of nanotechnology and drug delivery for IO